4.7 Article

Reimbursement of Dialysis: A Comparison of Seven Countries

期刊

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
卷 23, 期 8, 页码 1291-1298

出版社

AMER SOC NEPHROLOGY
DOI: 10.1681/ASN.2011111094

关键词

-

资金

  1. Fresenius Medical Care
  2. Baxter Healthcare
  3. Bellco
  4. Amgen
  5. Hofman-Laroche
  6. Nipro
  7. Janssen
  8. Genzyme
  9. Shire
  10. Baxter
  11. Takeda
  12. Leo
  13. Merck
  14. Novartis
  15. Ortho Biotech
  16. Vifor
  17. Litholink
  18. KAI
  19. DaVita
  20. Mitsubishi Tanabe
  21. Novashunt
  22. Reata

向作者/读者索取更多资源

Reimbursement for chronic dialysis consumes a substantial portion of healthcare costs for a relatively small proportion of the total population. Each country has Si unique reimbursement system that attempts to control rising costs. Thus, comparing the reimbursement systems between countries might be helpful to find solutions to minimize costs to society without jeopardizing quality of treatment and outcomes. We conducted a survey of seven countries to compare crude reimbursement for various dialysis modalities and evaluated additional factors, such as inclusion of drugs or physician payments in the reimbursement package, adjustment in rates for specific patient subgroups, and pay for performance therapeutic thresholds. The comparison examines the United States, the province of Ontario in Canada, and five European countries (Belgium, France, Germany, The Netherlands, and the United Kingdom). Important differences between countries exist, resulting in as much as a 3.3-fold difference between highest and lowest reimbursement rates for chronic: hemodialysis. Differences persist even when our data were adjusted for per capita gross domestic product. Reimbursement for peritoneal dialysis is lower in most countries except Germany and the United States. The United Kingdom is the only country that has implemented an incentive if patients use an arteriovenous fistula. Although home hemodialysis (prolonged or daily dialysis) allows greater flexibility and better patient outcomes, reimbursement is only incentivized in The Nether. lands. Unfortunately, it is not yet clear that such differences save money or improve quality of care. Future research should focus on directly testing both outcomes.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据